It is unlikely for Zydus Cadila to repeat US feat this year, say analysts

Analysts doubt if other Indian firms in the segment will do much better in the formulations business in the US

Analysts doubt if Cadila Healthcare (Zydus Cadila) will be able to replicate the 43 new product launches in the US it did in 2018-19. Also, they think, though high in terms of volume, the new US launches were not big enough to make significant dents in the market.

“It is unlikely for the firm to repeat the feat this year. Last year, the company had said it was going to launch 50 products, against which it launched 43. However, most of these products are smaller ones,” said an analyst, on condition of anonymity. 

Cadila’s annual report says FY19 was similar to FY18,